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Introduction
Gastro-oesophageal reﬂux disease (GERD) is a pre-
valent and chronic condition in which reﬂux of the
stomach contents into the oesophagus causes a range
of troublesome symptoms (including heartburn, acid
regurgitation and epigastric pain) and complications
(1). Such symptoms can cause marked disruption of
physical, social and emotional well-being (2,3), with
possible long-term complications of GERD including
reﬂux oesophagitis, haemorrhage, stricture, Barrett’s
oesophagus and adenocarcinoma of the distal oeso-
phagus (1).
The primary goals of GERD therapy are enduring
symptom relief, protection from long-term compli-
cations and improved subjective well-being. Proton
pump inhibitors (PPIs), which provide powerful
gastric acid control (4,5), are the treatment of
choice in this regard (1,6). Despite the prevalence
and impact of GERD, however, along with the
availability of effective treatments on prescription,
many subjects with symptoms suggestive of GERD
do not seek medical attention (7). Widespread self-
medication with over-the-counter (OTC) treatments
undoubtedly contributes to this problem of inad-
equate disease management.
In order to further investigate the relationship
between GERD symptoms, treatment and subjective
well-being, a large multinational survey was conduc-
ted in formally diagnosed GERD patients and undi-
agnosed subjects suffering from symptoms suggestive
of GERD.
Methods
Potential survey participants were identiﬁed via ran-
dom digit dialling of households in the USA, UK,
France and Germany. Respondents were screened for
eligibility and classiﬁed into one of two groups. The
ﬁrst group comprised patients who had been
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SUMMARY
Aim: To report data from a multinational survey investigating the relationship
between gastro-oesophageal reﬂux disease (GERD) symptoms, treatment and sub-
jective well-being. Methods: Patients formally diagnosed with GERD (n ¼ 929)
and undiagnosed subjects with symptoms suggestive of GERD (n ¼ 924) were
included. Results: Sixty per cent of diagnosed (mean age: 51.7 years) and 54%
of undiagnosed (mean age: 44.3 years) participants were female. Over 50% of
participants were overweight or obese. Most respondents consumed alcohol, and
one-third were smokers. In total, 78% of diagnosed subjects were currently receiv-
ing medication prescribed by their doctor, and 65% were taking over-the-counter
(OTC) treatments. The majority (97%) of undiagnosed subjects were taking OTC
medication, the most common of which were antacids (78%). Despite medication,
58% of diagnosed and 73% of undiagnosed subjects still experienced GERD symp-
toms some of the time. Approximately one-third of subjects in each group reported
that they ate less than usual, felt generally unwell, were tired/worn out or wor-
ried/fearful for the majority of the time because of their GERD symptoms, and
around half reported decreased well-being, including reduced work or leisure time
productivity. Conclusions: These ﬁndings attest to the severity and impact of
GERD symptoms, highlighting the need to improve the management of GERD in
routine practice. Many symptomatic and long-term sufferers, for example, may
beneﬁt from taking steps towards a healthier lifestyle (e.g. weight reduction) in
addition to optimisation of acid-suppressive therapy.
What’s known
• Gastro-oesophageal reﬂux disease (GERD) is a
prevalent and chronic condition in which reﬂux of
the stomach contents into the oesophagus causes
a range of troublesome symptoms that can cause
marked disruption of physical, social and
emotional well-being.
• Despite the prevalence and impact of GERD,
along with the availability of effective treatments
on prescription, many subjects with symptoms
suggestive of GERD do not seek medical
attention.
What’s new
• The ﬁndings of this large multinational survey
attest to the severity and impact of GERD
symptoms, highlighting the need to improve the
management of GERD in routine practice.
• The study also emphasises the need to raise
public awareness of GERD, in terms of both the
impact of long-term, under-treated GERD and the
options available for symptom relief.
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regurgitation or heartburn and had been prescribed
medication for their symptoms (either on the basis
of a clinical diagnosis or as a result of investigations).
The second group comprised undiagnosed sympto-
matic subjects, who had not approached a doctor
about their condition and had suffered heartburn or
acid regurgitation at least twice in the previous week
(identiﬁed using a screening questionnaire). The
sampling strategy dictated that the study population
was to include 50% formally diagnosed subjects, and
50% undiagnosed symptomatic subjects. The survey
was conducted in accordance with the MRS Code of
Conduct and the ICC/ESOMAR guidelines (available
at: http://www.esomar.org), and subjects provided
consent before proceeding with the interview.
Assenting participants underwent face-to-face,
computer-assisted interviews of maximum 45-min
duration. A 100-item questionnaire was used to
gather information about participants’ symptoms,
lifestyle and medication usage. Symptom severity was
rated by participants on a six-point scale (1 ¼ did
not have; 2 ¼ very mild; 3 ¼ mild; 4 ¼ moderate;
5 ¼ moderately severe; 6 ¼ severe). Subgroup analy-
ses were conducted on data received from diagnosed
participants currently receiving treatment with PPIs.
These participants were classiﬁed as being complete
responders, well-controlled, incomplete responders,
non-responders, or other, based on whether they
were currently experiencing key GERD symptoms
(acid regurgitation, heartburn or epigastric pain)
(Table 1). All statistical analyses were descriptive.
Results
In total, 212,099 households were identiﬁed via the
random digit dialling method. Some 56% of calls
(n ¼ 117,880) proved unsuccessful and there were
58,580 refusals (28%). For calls that were successfully
screened data were available for 1853 participants;
929 and 924 subjects, respectively, were assigned to
the diagnosed and undiagnosed cohorts. The demo-
graphic characteristics of the two groups are reported
in Table 2. Participants were mainly female and had a
mean (SD) age of 51.7 (15.9) years and 44.3 (15.4)
years in the diagnosed and undiagnosed groups
respectively. There were slightly more patients aged
‡ 55 years in the diagnosed than in the undiagnosed
group. Approximately 60% of the study population
were overweight [body mass index (BMI) 25–29.9 kg/
m
2] or obese (BMI ‡ 30 kg/m
2), and about the same
proportions were in full- or part-time employment.
Most respondents consumed alcohol, and one-third
were smokers. The two groups were generally com-
parable in terms of the distribution of these lifestyle
characteristics. Concomitant conditions were com-
mon among study participants, including hyperten-
sion, arthritis and hypercholesterolaemia. Arthritis
Table 1 Deﬁnition of response to treatment among subjects formally diagnosed with gastro-oesophageal reﬂux disease
(GERD) and receiving prescribed proton pump inhibitor (PPI) therapy
Category Criteria
Complete responders Suffered ‘no symptoms’* within the previous 7 days
Well controlled Suffered any key GERD symptom* on one of the previous 7 days
Reported that ‘symptoms have improved a lot’ or ‘symptoms improved
a little’ or that they experience symptoms ‘less frequently’ or ‘much
less frequently’ since ﬁrst taking PPI
Take prescribed PPI one to four times per day or ‘always’ or ‘usually’
take PPI as the label advises
Incomplete responders Suffered any key GERD symptom* on ‡ 2 of the previous 7 days
Reported that ‘symptoms have improved a lot’ or ‘symptoms improved
a little’ or that they experience symptoms ‘less frequently’ or ‘much
less frequently’ since ﬁrst taking PPI
Take prescribed PPI one to four times per day or ‘always’ or ‘usually’
take PPI as the label advises
Non-responders Reported that ‘symptoms stayed the same’ or ‘symptoms worsened’
since ﬁrst taking PPI
Take prescribed PPI one to four times per day or ‘always’ or ‘usually’
take PPI as the label advises
Other All PPI users who do not ﬁt into the above categories
*Acid regurgitation, heartburn or epigastric pain. GERD, gastro-oesophageal reﬂux disease. Patients had to meet all of the listed cri-
teria to be assigned to the respective category.
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non-steroidal anti-inﬂammatory drugs (NSAIDs) was
more common among the diagnosed than the undi-
agnosed subjects. The most common NSAIDs in both
groups were ibuprofen (11% and 15% in the diag-
nosed and undiagnosed groups respectively) and
‘others’ (25% and 17% respectively).
Symptoms
Subjects in the diagnosed population had experi-
enced symptoms suggestive of GERD for an average
of 10.8 years. In the undiagnosed group, the mean
length of time since symptoms were ﬁrst experienced
was 7.7 years. Symptoms were mainly mild or mod-
erate in severity (Table 3). More subjects reported
severe heartburn or acid regurgitation in the diag-
nosed than in the undiagnosed group (32% vs. 23%
and 30% vs. 18%). In the diagnosed group, over
two-thirds of respondents (67%) waited for up to
6 months before consultation and 11% waited over
4 years. For undiagnosed patients, the most frequent
reasons for not consulting a doctor were that ‘non-
prescription medicines work effectively’ and that ‘I
have control of my symptoms’.
Common trigger factors for GERD symptoms
included eating (80% and 84% in the diagnosed
and undiagnosed subjects respectively), stress (30%
and 28% respectively) and physical activity (18% and
14% respectively). Most subjects reported that they
had attempted to change their lifestyle accordingly to
try and avoid or limit the impact of these trigger fac-
tors, but symptoms often continued to be experi-
enced at least some of the time.
Current medications for GERD
Among diagnosed participants, PPIs were the most
commonly prescribed treatment, followed by antacids
and H2-receptor antagonists (H2RAs) (Figure 1). Use
Table 2 Characteristics of study participants (n ¼ 1853)
Characteristic
Diagnosed
subjects,
n ¼ 929
(%)
Undiagnosed
subjects,
n ¼ 924
(%)
Female gender 60 54
Age, years
18–30 11 21
31–54 44 51
‡ 55 45 28
Body mass index*
Normal 40 47
Overweight 38 35
Obese 21 17
Working status
Working full- or part-time 53 64
Not working 47 36
Smoker 28 38
Alcohol consumption
Frequently (daily or more
than 2–3 times per week)
29 34
Occasionally (up to
once per week)
41 43
Never 25 19
Not reported 1 0
Other conditions
Hypertension 16 13
Arthritis 13 8
Hypercholesterolaemia 11 10
Migraine 8 9
Diabetes 8 6
Anxiety 9 7
Asthma 7 7
Concomitant use of NSAIDs 22 14
*Overweight and obese deﬁned as body mass index of
25–29.9 and ‡ 30 kg/m
2 respectively. NSAID, non-steroidal
anti-inﬂammatory drug.
Table 3 Severity of symptoms in diagnosed and undiagnosed subjects
Severity of symptom*
Symptom (% subjects)
Heartburn Acid regurgitation Acid taste Belching Indigestion Bloating
Diagnosed subjects n ¼ 602 n ¼ 482 n ¼ 279 n ¼ 248 n ¼ 232 n ¼ 227
Mild 26 24 30 38 33 30
Moderate 41 44 38 34 34 37
Severe 32 30 30 26 31 33
Undiagnosed subjects n ¼ 710 n ¼ 475 n ¼ 295 n ¼ 249 n ¼ 225 n ¼ 200
Mild 36 38 43 44 39 37
Moderate 41 43 36 37 40 35
Severe 23 18 20 18 20 27
*Among patients reporting the symptom. Values do not necessarily total 100% because of rounding and missing data.
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nosed subjects; 52% of subjects were taking antacids,
10% were taking H2RAs and 3% were taking PPIs.
The majority (97%) of undiagnosed symptomatic
subjects were currently taking OTC medication, the
most common of which was antacids (78%). In gen-
eral, these participants had been using OTC medica-
tion for 1–4 years.
Self-reported adherence to treatment prescribed by
a doctor was generally good. Some 71% of diagnosed
participants reported that they ‘usually’ or ‘always’
took their prescribed medicine as the label advised.
Some 35% of diagnosed patients reported that they
often took their prescribed medication in anticipa-
tion of symptoms occurring. High levels of self-
reported adherence were also observed among
PPI-treated patients. Adherence was poor in patients
taking OTC medication; only 53% of diagnosed and
53% of undiagnosed participants took their medica-
tion as the label advised. Approximately one-third of
all subjects in each group took their OTC medication
prophylactically.
Effects of current medication on symptoms
Symptoms were not completely alleviated with cur-
rent treatments. Among diagnosed patients, 58%
reported that they continued to experience symptoms
‘some of the time’, although the majority reported
that symptoms had improved [in terms of severity
(84%) and frequency (73%)] since they ﬁrst started
treatment. Only one-third (33%) of diagnosed
patients responded that they were ‘very satisﬁed’ with
treatment [the corresponding value among those
receiving PPIs (n ¼ 537) was 36%].
Of the subgroup of diagnosed patients receiving PPI
treatment who were evaluable for response (n ¼ 482),
only 186 (39%) were classiﬁed as either complete
responders (n ¼ 125) or well controlled (n ¼ 61); 247
(51%) were incomplete responders and 49 (10%) were
non-responders. Patients in the latter group were
more likely to use OTC medications in addition to
their PPI (71% vs. 42% of complete responders and
56% of well-controlled subjects).
Forty-seven per cent of undiagnosed subjects
reported no change in the frequency of their symp-
toms since ﬁrst taking OTC medication. Similarly,
28% reported no change in the severity of their
symptoms.
Effects of symptoms on subjective well-being
and productivity
Sleep disturbances attributed to symptoms were repor-
ted in approximately half of both diagnosed (55%)
and undiagnosed (45%) participants who had experi-
enced any symptom of GERD in the past 7 days. Diag-
nosed subjects reported that they had been woken by
their symptoms an average of 3.0 times in the past
7 days, compared with 2.7 times in undiagnosed sub-
jects. The mean duration of night-time wakefulness
was estimated at 74.9 and 62.5 min, respectively, per
episode. Of the subgroup of diagnosed patients receiv-
ing PPI treatment, the extent of sleep disturbance
decreased with increasing level of symptom control
and response to treatment (Figure 2).
Gastro-oesophageal reﬂux disease symptoms were
perceived to impact negatively on both professional
and leisure activity; approximately half of partici-
pants in each group estimated that work and leisure
time productivity were mildly or moderately affected
by their GERD symptoms (Figure 3A,B). Both
employed diagnosed and undiagnosed subjects repor-
ted that they were absent from work for a mean of
20 min per week because of problems associated with
their GERD symptoms.
Gastro-oesophageal reﬂux disease symptoms were
also perceived to have detrimental effects on other
aspects of subjective well-being. Considering the last
7 days, approximately one-third of diagnosed and
0 1 02 03 04 05 06 0
PPI
Antacids
H2RA
Other
No therapy
Patients (%)
Figure 1 Current medicines prescribed by a doctor in
participants with a formal diagnosis of gastro-oesophageal
reﬂux disease (n ¼ 929); multiple responses possible. PPI,
proton pump inhibitor; H2RA, H2-receptor antagonist
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Figure 2 Extent of sleep disturbance in relation to the level
of symptom control among diagnosed patients receiving
treatment with a proton pump inhibitor (n ¼ 537)
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usual (46% and 38% respectively) or that they felt
generally unwell (37% and 34% respectively), were
tired/worn out (37% and 29% respectively) or wor-
ried/fearful (27% and 22% respectively) the majority
of the time because of their symptoms. Of the sub-
group of diagnosed patients receiving PPI treatment,
the impact of GERD on these aspects of well-being
was decreased for those who were complete respond-
ers or well controlled (Figure 4).
Discussion
This large, multinational survey is the ﬁrst to report
data from both formally diagnosed GERD patients
and undiagnosed subjects experiencing symptoms
suggestive of GERD. An important ﬁnding is that
GERD symptoms were persistent in many diagnosed
respondents despite the use of medicines prescribed
by a doctor, including PPIs. Poor symptom control
in our study probably explains why a high propor-
tion of patients taking medication prescribed by their
doctor were also taking OTC medicines. These
results are similar to those observed in a recent study
(7), in which 20.5% of patients receiving any therapy
prescribed by a doctor for GERD were also taking
OTC medicines, the main reason for which was that
‘prescription therapy alone was not effective’. Simi-
larly, Fass et al. (8) reported that 30% of patients
classiﬁed as having GERD and receiving PPI treat-
ment continued to experience symptoms.
A variety of factors may contribute to failure of
therapy prescribed by a doctor to provide enduring
relief of symptoms, including poor treatment adher-
ence. Patients may take their medication on an
‘on-demand’ basis (whether they are told to or not)
and it is inevitable that they will subsequently continue
to experience symptoms because taking medication is
triggered by symptom recurrence. However, self-
reported treatment adherence was generally fairly high
in patients taking medication prescribed by their doc-
tor. We are unable to comment on the possibility that
symptom control is better in the 35% of patients who
took their prescribed medication prophylactically, but
recognise that this may be an appropriate approach to
symptom-led treatment. It is unlikely, therefore, to
have been an issue in the present study. Instead, poor
symptom control may have been attributable to non-
acid or weakly acidic reﬂux, such as duodenogastro-
oesophageal reﬂux or functional heartburn (9,10), or
delayed gastric emptying and/or visceral hypersensitiv-
ity. The diagnosis, therefore, should be carefully
reviewed, especially among non-responders.
Use of OTC medication was a common ﬁnding in
the present study, with many undiagnosed subjects
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an alternative to seeing their doctor. This is a recog-
nised phenomenon, and outlines the need for greater
awareness among the general population as to the
potential seriousness of GERD and the need to con-
sult a doctor for appropriate treatment.
Symptom-induced sleep disturbances, with resul-
tant daytime sleepiness, are likely to have contributed
to the decreased work and leisure time productivity
observed in our study. Indeed, this effect was partic-
ularly pronounced in subjects with a lack of response
to PPI treatment. Our ﬁndings are therefore consis-
tent with those of a previous study (11), in which
nocturnal symptoms were negatively associated with
work productivity.
Important limitations of this study, which may
limit applicability of the results to the general popu-
lation, are the reliance on self-reported data, the
potential bias towards subjects willing to participate
in survey research and the lack of a control group
without GERD-like symptoms. Furthermore, the high
levels of self-reported treatment adherence may well
have been overestimated, as most patients are likely
to reply positively to the question ‘Do you always
take your medicine as the label advises?’ Similarly,
the reported effects of symptoms on sleep, productiv-
ity and general well-being in this survey should be
interpreted cautiously, as subjective estimations
rather than a validated questionnaire were used to
gather information on well-being. The inﬂuence of
other confounding factors on well-being, such as age,
obesity and concomitant conditions, must also be
considered. In the present study, the diagnosed
population comprised more patients aged ‡ 55 years
than the undiagnosed population. In addition, the
prevalence of arthritis was higher in the diagnosed
population, which may be a reﬂection of the older
age of these subjects. Concomitant NSAID use was
also higher in diagnosed than in undiagnosed sub-
jects, which is likely to be as a result of the presence
of age-related conditions such as arthritis, and this
may have contributed to their symptoms. A higher
prevalence of NSAID use could also be a result of
the fact that subjects in the diagnosed group may be
more likely to visit their doctor, and therefore receive
medication prescribed by a doctor, than those in the
undiagnosed group. The use of an age-matched con-
trol group without GERD-like symptoms would
allow better understanding of the effects of symp-
toms on subjective well-being. A further limitation is
that there may be an over-representation of ‘incom-
plete responders’ in our study compared with the
general population, given that diagnosed patients
with well-controlled symptoms were probably less
likely to have entered the study.
The perceived burden of symptoms on well-being
among subjects in our study demonstrates a consid-
erable unmet need for enduring relief of symptoms
among subjects with conﬁrmed, or suspected, GERD.
Indeed, long-term sufferers and persistently sympto-
matic subjects may beneﬁt from a careful review of
their symptoms and optimisation of acid-suppressive
therapy by switching to another more potent PPI.
Doctors should also encourage their patients to
adopt a healthier lifestyle, given that the survey
revealed many subjects to be smokers, regular con-
sumers of alcohol and/or overweight or obese. It is
notable, however, that many respondents had
attempted to modify their lifestyle in order to con-
trol their symptoms but with limited success, which
is in agreement with the recent evidence-based analy-
sis of Kaltenbach et al. (12). Perhaps the strongest
educational message is that overweight or obese sub-
jects should be encouraged to lose weight, given that
this can help improve symptoms (12). Many sympto-
matic subjects may beneﬁt from weight loss (as part
of a healthier lifestyle) in addition to optimisation of
acid-suppressive therapy, recognising of course that
certain activities may themselves exacerbate symp-
toms and should be avoided.
Conclusions
In summary, the ﬁndings of this study show that
GERD symptoms may persist despite treatment with
OTC agents or medicines prescribed by a doctor
and, in turn, such symptoms have a signiﬁcant
impact on subjective well-being. A need therefore
exists to improve the management of GERD in rout-
ine practice to ensure that patients achieve enduring
relief from the disruption and frustration caused by
their symptoms. In particular, it would be useful to
identify long-term sufferers and those with inad-
equate symptom control who may beneﬁt from more
effective acid-suppressive therapy, while the diagnosis
should be carefully reviewed among the small pro-
portion of non-responders who may have a different
cause for their symptoms.
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